WO2008153572A1 - Construction de prrsv chimères, compositions et préparations vaccinales - Google Patents

Construction de prrsv chimères, compositions et préparations vaccinales Download PDF

Info

Publication number
WO2008153572A1
WO2008153572A1 PCT/US2007/071341 US2007071341W WO2008153572A1 WO 2008153572 A1 WO2008153572 A1 WO 2008153572A1 US 2007071341 W US2007071341 W US 2007071341W WO 2008153572 A1 WO2008153572 A1 WO 2008153572A1
Authority
WO
WIPO (PCT)
Prior art keywords
prrsv
replicon
seq
virus
sequence
Prior art date
Application number
PCT/US2007/071341
Other languages
English (en)
Inventor
Xuexian Zhang
Shi-Jun Ma
Original Assignee
Protatek International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protatek International, Inc. filed Critical Protatek International, Inc.
Priority to PCT/US2007/071341 priority Critical patent/WO2008153572A1/fr
Priority to CNA2007800005728A priority patent/CN101454442A/zh
Publication of WO2008153572A1 publication Critical patent/WO2008153572A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to molecular virology. More particularly, the invention encompasses methods of attenuating Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) and viral compositions that include attenuated PRRSV.
  • PRRSV Porcine Reproductive and Respiratory Syndrome Virus
  • Porcine Reproductive and Respiratory Syndrome is the most economically significant disease affecting the swine industry, with an estimated annual loss of up to $560 million in the United States.
  • Primary symptoms of the disease are reproductive problems in sows and gilts, including late-term abortions, stillbirths and mummies, as well as litters of small weak pigs that are born viremic and often fail to survive.
  • the syndrome may be manifested as a respiratory disease in young pigs which causes fever, lethargy, labored breathing, loss of appetite, slow growth and occasionally death, often in association with other respiratory pathogens.
  • the disease can also be transmitted to sows and gilts via the semen of infected boars, either naturally or by artificial insemination.
  • PRRSV is a member of the Arteriviridae, which belongs to the order of Nidovirales along with the Coronaviridae. It is a positive-stranded RNA virus which encodes 7 to 10 open reading frames (ORFs), flanked with the 5' and 3' terminal untranslated regions (UTRs). It is believed that the UTRs contain the cis-acting regulatory elements for genomic and subgenomic RNA replication and transcription.
  • the PRRSV virion is composed of six structural proteins (encoded by ORPs 2 to 7).
  • the product of ORF5 plays a critical role in virus entry of cells and stimulates neutralizing immunity.
  • the ORF5 sequence represents the most variable region in the genome, which contributes to diverse genetic and antigenic variations of the virus. The genetic diversity of PRRSV has complicated efforts to develop an effective vaccine against PRRSV disease and its related syndromes.
  • PRRSV vaccines there are commercial PRRSV vaccines available, including live-attenuated and killed virus vaccines. Unfortunately, the available vaccines have not exhibited sufficient immunoprotection in vaccinated herds. Safety of the live-attenuated vaccines has also been called into question. Moreover, current vaccines offer little protection against heterologous challenge by genetically diversified PRRSV strains. In addition, current vaccines provide no features for differentiating the natural infection from vaccine strains. Vaccines exhibiting significant improvements in safety, efficacy and identification are needed.
  • Virus attenuation through cell culture passage adversely affects the efficacy of vaccine derived from attenuated viruses in several respects.
  • the replication ability of the vaccine virus is affected under the fitness selection.
  • high- level attenuation through cell culture creates antigenic variation due to the high mutation rate of an RNA virus. Therefore, a conventional attenuated vaccine would not offer the cross- protection against other forms of genetically diversified PRRSV isolates.
  • an attenuated virus that has growth characteristics and antigenic abilities to protect against homologous and heterologous strains of PRRSV.
  • the inventors have discovered a region of the PRRSV genome which encodes for the virulence factors of PRRSV.
  • This discovery provided the basis for development by the inventors of a novel approach for attenuation of field isolated virulent stains of PRRSV.
  • the virulent region of the virus is substituted with the corresponding region from an avirulent strain to produce a chimeric virus.
  • the chimeric virus is non-pathogenic in host animals, yet provokes a protective immune response to homologous and heterologous PRRSV challenge.
  • This approach provides an alternative to serially-passaged attenuated virus vaccines.
  • the vaccine compositions described herein provide cross-protection against diversified PRRSV isolates.
  • the invention provides a chimeric PRRSV replicon.
  • the replicon includes a 5' sequence derived from an avirulent strain of PRRSV and a 3' sequence derived from a virulent stain of PRRSV.
  • the 5' sequence includes ORFl, ORF2, a portion of ORF3, or a combination thereof and the 3' sequence sufficiently completes the genome such that the replicon is capable of producing an infectious virus particle that is attenuated relative to the virulent strain.
  • the invention provides a method of producing an infectious attenuated chimeric PRRSV.
  • the method includes transfecting a cell with a replicon comprising a 5' sequence derived from an avirulent strain of PRRSV and the 3' sequence derived from a virulent strain of PRRSV.
  • the 5' sequence includes ORFl, ORF2, part of ORF3, or a combination thereof, and a 3' sequence that sufficiently completes the genome such that the replicon is capable of producing an infectious viral particle.
  • the method further includes steps of incubating the cell under conditions suitable for production of infectious virus particles and recovering the virus particles, wherein the recovered virus is attenuated relative to the virulent strain of PRRSV.
  • the invention includes the attenuated virus produced from the method described above, compositions comprising the attenuated virus or replicon, and vaccines comprising the composition.
  • FIG. 1 is a schematic drawing depicting the construction of a chimeric PRRSV replicon including a genetic marker (PSA), a 5' sequence from clone pB13117, and a 3' sequence derived from a virulent field isolate of PRRSV.
  • FIG. 2 is a bar graph showing a reduction in gross lung lesions caused by PRRSV infection at day 49 post- vaccination of pigs vaccinated with a chimeric virus of the invention, termed "PRRSPTK-3", and an avirulent strain ptkPRRS as compared with control pigs after challenge with virulent strains of PRRSV (NADC-20 or MNl 84).
  • FIG. 3 is a graph depicting the increased in PRRSV-specific antibodies in serum of pigs vaccinated with a chimeric virus of the invention, termed "PRRSPTK-3", and an avirulent strain ptkPRRS as seen by increased S/P values over time.
  • FIG. 4A is a graph showing pigs vaccinated with a combination of chimeric virus of the invention, termed "PRRSPTK-3", and an avirulent strain ptkPRRS had comparable body weight gain to the non- vaccinated control pigs over time.
  • FIG. 4B is a bar graph depicting weight gain results from pigs vaccinated with a combination of chimeric virus of the invention, termed "PRRSPTK-3", and an avirulent strain ptkPRRS followed by challenge with a virulent strain of PRRSV.
  • FIG 5 is a graph showing the body temperature of pigs vaccinated with a combination of a chimeric virus of the invention, termed "PRRSPTK-3", and an avirulent strain ptkPRRS and non-vaccinated pigs over time.
  • PRRSPTK-3 a combination of a chimeric virus of the invention
  • the present invention relates to chimeric PRRSV replicons for producing an attenuated infectious PRRSV chimera. Furthermore, the invention relates to methods of producing such strains and use of such strains in vaccines.
  • a "PRRSV replicon" as described herein is a DNA molecule or RNA molecule, or a region of DNA or RNA that replicates from a single origin of replication, i.e., a plasmid, cDNA clone, or vector.
  • replicon encompasses cDNA generated from PRRSV viral genomic RNA via in vitro techniques, cDNA resulting from the reverse transcription of genomic RNA, vectors incorporating such cDNA, cDNA fragments produced by RT-PCR or restriction endonuclease digestion and recombinant nucleotide sequences that contain synthetic coding or non-coding sequences.
  • the replicon is capable of in vivo RNA replication and production of an infectious PRRSV viral particle.
  • the replicon transcribed in vitro or in vivo by host cell RNA polymerase is capable of completing the viral infectious cycle in host cells.
  • the replicon includes a 5' sequence from an avirulent strain of PRRSV and a 3' sequence from a virulent strain of PRRSV.
  • a "5' sequence of an avirulent strain of PRRSV” refers to any portion of a sequence identical or corresponding to the first 13117 base pairs of SEQ ID NO: 1.
  • ORFIa spans nucleotides 192- 7798
  • ORPIb spans nucleotides 7797-12181
  • ORF2 spans nucleotides 12183-12953
  • the partial sequence of ORF3 spans nucleotides 12806-13117.
  • the sequence of ORF 1-3 may differ.
  • the 5' sequence is suitably derived from any attenuated PRRSVstrains, such as ptkPRRS (SEQ ID NO: 1), ptk- PRRS-I (SEQ ID NO 2), avirulent strains described in U.S. Patent No, 6,841,364, serially- passaged strains that exhibit reduced virulence, or other avirulent strains known in the art.
  • the 3' sequence is derived from a virulent strain, e.g., a field isolated PRRSV, and supplies all necessary sequences for the chimera to produce an infectious viral particle, i.e., it completes the genome.
  • Suitable virulent strains are strains isolated from serum of infected pigs by means known in the art. Examples include strains termed "MN- 184,” “NADC-20,” and VR- 2332.
  • Virulence of a virus refers to the ability of a virus, when compared with other closely related viruses, to produce pathogenicity in a host.
  • a "virulent" strain causes disease, i.e., abortions, early furrowing, increased stillbirths, mummies and pre- weaning mortality and infertility in infected sows and gross lung lesions and pneumonia and increased mortality in suckling and fattening pigs and increased susceptibility to secondary infections.
  • "Avirulent" strains are strains where the virulence of a strain has been attenuated, e.g., reduce the symptoms of PRRSV infection in a pig relative to the virulent strain.
  • the attenuation of virulence of an avirulent strain may be evaluated by a reduction in the gross histopathological changes (e.g., lung lesions) and/or reduction in the symptoms of the disease, as compared to a control.
  • Symptoms of PRRSV include, but are not limited to, e.g., fever, respiratory distress, lethargy, forced expiration, sneezing, coughing, eye edema, or roughened haircoats. Methods of evaluating symptoms are known in the art.
  • Attenuation of a virulent strain of PRRSV may be measured by reduction of lung lesions, e.g., as described in the examples below.
  • the number of lung leasions is reduced at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 100%, at least 200% relative to a non-vaccinated control.
  • Virulence of a chimera is suitably compared to the virulent "parental" strain of PRRSV and reduced virulence clones may be selected as suitable vaccine candidates.
  • virulence of chimeric PRRSV in comparison to a field isolate may be tested by the methods described in Example 8, i.e., by examination of lung lesions, growth performance, sero-conversion and body temperature of pigs infected with the chimeric PRRSV strain. Any other suitable method of testing virulence may be used.
  • the chimera of PRRSV contains 5' and 3' sequences that, in combination, complete a full-length infectious replicon, e.g., ORF 1-7.
  • the full- length infectious replicon may contain insertions or deletions that do not affect the ability of the replicon to produce infectious particles, and these insertions and deletions may alter the number or sequence of nucleotides in the full-length replicon without affecting function.
  • the 5' sequence from the avirulent strain contains the 5' untranslated region (UTR), ORFIa and ORFIb
  • the 3' sequence from the field isolate will contain the sequence for ORF2-7 and 3' UTR to produce a full-length replicon.
  • sequence "derived from" a reference sequence refers to a synthetic peptide or polynucleotide or a sequence prepared by molecular biology methods, using an isolated strain of virulent or avirulent PRRSV as a template.
  • the resultant chimeric replicon contains all the necessary nucleotides and amino acids to produce an infectious viral particle, for example ORF 1-7. It is understood that replicons of the invention may be of any length, and include additions or deletions that do not affect the ability of the replicon to produce infectious viral particles.
  • An "infectious" viral particle is a virus with all the necessary components to enter and replicate within a cell.
  • PRRSV replicons suitably further comprise a genetic marker sequence.
  • a "genetic marker sequence” is a sequence that is inserted into the PRRSV genome without altering viral gene expression, which can be used to identify replicons or viral progeny. Identification of the marker sequence is suitably accomplished by isolation of the sequence followed by sequencing or restriction enzyme digestion and fragment visualization techniques that are well-known in the art. As will be appreciated, genetic modifications of PRRSV DNA of the invention will be useful as a means of differentiating engineered PRRSV from that of field isolates or commercial vaccine strains. Genetic marker sequences are added by suitable means to the engineered replicon for later identification.
  • PRRSV replicons comprising an MwI site introduced by substitution in ORF5, an Ndel site introduced by insertion in the 3' UTR, Pad, Swal, Ascl or Vspl sites introduced by insertion at the junction of ORFl and ORF2, or by deletion of sequences in the 3' end of the ORF7 and 5' part of ORF2 or in the middle of ORF4, as described in U.S. Patent No. 6,841,364. It is contemplated that any suitable restriction digestion site or polylinkers may be used to "mark" chimeric PRRSV DNA in the practice of this invention.
  • the invention provides a cell comprising the replicon described above.
  • the cell is not limited to any particular cell type, but must be capable of expressing the replicon to provide infectious RNAs or viral particles under suitable conditions.
  • the cell may be permissive and/or susceptible.
  • Permissive cells are cells which can be used by the virus to replicate and produce viral particles upon introduction of viral RNA or infectious cDNA. Permissive cells may or may not have a cell surface receptor for the virus.
  • "Susceptible” cells are cells bearing surface receptors for the virus, and which can be used by the virus to complete multiple cycles of proliferation and infection. Examples of suitable cells include, but are not limited to, simian cell lines and porcine cells.
  • Simian kidney cell lines are suitable for in vitro applications. Once such line, African Green Monkey continuous cell line MA- 104, as well as its progeny line Marc 145, are commercially available.
  • PRRSV exhibits tropism for lung alveolar macrophages in vivo and these cells are also suitable in vitro multiplicity of PRRSV.
  • the invention provides a method of producing an attenuated infectious PRRSV virus.
  • the method includes steps of transfecting a cell with a replicon described above, incubating the cell under conditions suitable for production of an infectious virus particle, and recovering the virus particle.
  • In vitro delivery methods of the replicon into a cell include, but are not limited to, transfection (including microinjection, electroporation, calcium phosphate precipitation, using DEAE- dextran followed by polyethylene glycol, direct sonic loading, liposome-mediated transfection and receptor-mediated transfection), transduction by viral vector, and/or any combination of such methods.
  • Methods that can be used to recover virus particles from cells are well known in the art, e.g., the method of Example 5.
  • the cells are cultured under conditions that allow expression of the replicon. Typically, standard culture conditions are sufficient.
  • an attenuated virus produced from a chimeric replicon has similar growth kinetics to a virulent stain of PRRSV.
  • "Substantially identical growth kinetics" of a virus can be monitored in vitro by measuring the viral titer over time where the titer is within about 10% of a reference strain. The growth kinetics of the chimeric virus are suitably compared to the virulent strains from which the chimera is derived.
  • compositions including the chimeric replicon or attenuated virus are also within the scope of the invention.
  • Such compositions typically include the replicon or chimeric virus and a physiologically acceptable vehicle.
  • a "physiologically acceptable" vehicle is any vehicle that is suitable for in vivo administration (e.g., oral, transdermal or parenteral administration) or in vitro use, i.e., cell culture.
  • Suitable physiologically acceptable vehicles for in vivo administration include water, buffered solutions and glucose solutions, among others.
  • a suitable vehicle for cell culture is commercially available cell media.
  • compositions may suitably include excipients such as stabilizers, preservatives, diluents, emulsifiers or lubricants, in addition to the physiologically acceptable vehicle and the replicon or attenuated virus.
  • excipients include, but are not limited to, Tween 20, DMSO, sucrose, L-histadine, polysorbate 20 and serum.
  • Some embodiments of the invention provide a method of stimulating an immune response in a mammal.
  • the mammal is a porcine species.
  • Stimulating an immune response includes, but is not limited to, inducing a therapeutic or prophylactic effect that is mediated by the immune system of the mammal. More specifically, stimulating an immune response in the context of the invention refers to eliciting cellular or humoral immune responses, thereby inducing downstream effects such as production of antibodies, antibody heavy chain class switching, maturation of APCs, and stimulation of cytolytic T cells, T helper cells and both T and B memory cells.
  • the immune response stimulated according to the invention by a chimeric virus may suitably promote a reduction in symptoms in the mammal as compared to the virulent strain.
  • compositions are suitably formulated to be compatible with the intended route of administration.
  • suitable routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • a suitable route of administration to swine is intramuscularly.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH of the composition can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • compositions of the invention are suitably formulated as a vaccine.
  • vaccine refers to a composition which, when administered to a subject, induces cellular or humoral immune responses as described herein.
  • the effectiveness of the present vaccine may be evaluated by a reduction in the gross histopathological changes (e.g., lung lesions, mycocarditis, lymphadenitis, encephalitis and rhinitis) and/or reduction in the symptoms of the disease, as compared to similar pigs that are not vaccinated or are administered a negative control before challenge by a field strain, e.g., as described in the examples below.
  • Symptoms of PRRSV include, but are not limited to, e.g., fever, respiratory distress, lethargy, forced expiration, sneezing, coughing, eye edema, or roughened haircoats.
  • Effectiveness of a vaccine may be measured by reduction of lung lesions.
  • the number of lung lesions is reduced at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 100%, at least 200% relative to a non-vaccinated control.
  • Suitable vaccine compositions include an infectious PRRSV replicon produced according to the invention or RNA or antigenic peptides produced in vitro from infectious PRRSV replicons. Additional suitable vaccine compositions include whole live attenuated virus produced using the replicon of the invention. Suitable vaccines also include the combination of two or more whole live attenuated chimeric viruses produced using replicons of the invention. Vaccine compositions may include an aqueous medium, pharmaceutically acceptable inert excipient such as lactose, starch, calcium carbonate, and sodium citrate. Vaccine compositions may also include an adjuvant, for example Freud's adjuvant.
  • Vaccines may be administered alone or in combination with a physiologically acceptable vehicle that is suitable for administration to swine.
  • Vaccines may be delivered orally, parenterally, intramuscularly, intranasally or intravenously. Oral delivery may encompass, for example, adding the compositions to the feed or drink of the mammals. Factors bearing on the vaccine dosage include, for example, the weight and age of the mammal.
  • Compositions for parenteral or intravenous delivery may also include emulsifying or suspending agents or diluents to control the delivery and dose amount of the vaccine.
  • Vaccines are suitably delivered in one intramuscular injection of about 1 x 10 4 to 1 x 10 6 virions per administration.
  • Example 1 Addition of a genetic marker sequence to an infectious avirulent PRRSV clone.
  • a genetic maker, PacVSwaVAscl (PSA) polylinker (SEQ ID NO: 3) was inserted into the viral genome between ORF Ib and 2 without altering viral gene expression to identify vaccine virus from field isolates of PRRSV.
  • the ptkPRRS clone (SEQ ID NO: 1, from US Patent No. 6,841,364) was used to construct the modified viral genome.
  • PCR amplification was performed using two primer pairs, SF7682/PSA1R (SEQ. ID NO: 4/SEQ ID NO: 5) and PSA2F/Sp2R (SEQ ID NO: 6/SEQ ID NO: 7).
  • Obtained PCR products were digested with restricted endonuclease PmeVPacl and Pacl/Xhol, respectively, and purified by an agarose gel.
  • the ptkPRRS plasmid DNA was digested with Pme ⁇ and Xhol and purified by agarose gel.
  • a ligation reaction was performed with digested plasmid DNA ptkPRRS, SF7628/PSA1R fragment, and PSA2F/Sp2R fragment.
  • the new recombinant infectious clone was called as ptkPRRS-1 (SEQ ID NO: 2), in which PSA polylinker is located between ORFl and ORF2.
  • PCR was performed with a primer pair: PSA polylinker/SR12709(SEQ ID NO: 8/SEQ ID NO: 9). Furthermore, restriction endonuclease Pad, Ascl, and Swal were used to digest the recombinant plasmid DNA and verified the modified PRRSV, ptkPRRS- 1, includes a genetic marker PSA in viral genome.
  • Example 2 Subcloning of the 5' sequence of an avirulent strain of PRRSV (13117bp) into pBluescript SK(+). A subclone from clone ptkPRRS-1 was constructed to remove the 3 'end of viral genome by using a unique restriction endouclease site Spel in ptkPRRS- 1. Plasmid DNA of the clone ptkPRRS- 1 was digested with iVotl and Spel and the 5 'end fragment containing ORF 1, ORF2 and partial sequence of ORF3 (13117 bp, SEQ ID NO: 10) was purified on an agarose gel.
  • the purified fragment was cloned into plasmid vector pBluescript SK(+) (Stratagene, La Jolla, CA). This recombinant clone, designated as pB13117, was used as a backbone to construct a chimeric infectious clone of PRRSV.
  • pB13117 This recombinant clone, designated as pB13117, was used as a backbone to construct a chimeric infectious clone of PRRSV.
  • Example 3 Subcloning of the 3' sequence of a field isolate strain of PRRSV into vector pCR-Blunt. QIAamp Viral RNA Kit (Qiagen, Valencia, CA) was used to extract viral RNAs from porcine serum or cell culture supernatants.
  • Porcine serum or cell culture supernatants from viral infection and buffer AVL with carrier RNA were added into a microcentrifuge tube (560 ⁇ l of AVL buffer with 140 ⁇ l of sample; both are proportionally). After mixing by pulse-vortexing for 15 seconds, the lysis was incubated at room temperature for 10 min, and then 560 ⁇ l of ethanol was added into the sample. After briefly mixing, sample was loaded into column and centrifuged at 8000 rpm for 1 min (Repeat it until all lysis solution is loaded). The column with sample was washed orderly with AWl and AW2 buffer. Finally, RNAs were eluted with the elution buffer and stored at -8O 0 C.
  • the First-strand cDNA was synthesized using the Superscript II Reverse Transcription Kit (Invitrogen, Carlsbad, CA) with the anchor primer SP2R (SEQ ID NO: 7).
  • PCR amplification of target genomic region was conducted by the use of Pfu Turbo Hotstart DNA polymerase (Stratagene, La Jolla, CA) according to the protocol described by the manufacturer with the 1 st stranded cDNA and primers.
  • synthesized forward primer SpeF (SEQ ID NO: 11) and anchor primer Sp2R (SEQ ID NO: 7) were used for amplification of the structural protein-coding region covering partial ORF3 through ORF7 from two field isolated strains, a portion of MN- 184, SEQ ID NO: 12, or a portion of a new field isolate, SEQ ID NO:17.
  • Gel-purified PCR product was cloned directly into pCR-Blunt vector according to the procedure described by the manufacturer (Invitrogen, Carlsbad, CA). This clone is designated as pCR-Blunt-3-7.
  • Example 4 Construction of chimeric full-length replicon of PRRSV.
  • pPRRSPTK-3 included the 3' sequence of field strain MN- 184 (SEQ ID NO: 12)
  • pPRRSPTK-6 included the 3' sequence of a new field strain isolated (SEQ ID NO: 17).
  • the two clones were further characterized by restriction endonuclease digestion of recombinant plasmid DNAs and DNA sequencing.
  • Example 5 Formation of chimeric PRRSV in Marc 145 cells.
  • DNAs of chimeric infectious PRRSV clone were transcribed in vitro.
  • Marc 145 cells were transfected with the synthesized RNAs.
  • the two full-length clones, pPRRSPTK-3 and pPRRSPTK-6, were linearized with a restriction endonuclease Xhoil at the downstream of the clones.
  • the linearized template DNA was examined on an agarose gel to confirm that the cleavage is complete. Purified DNAs were used to perform in vitro transcription with mMESSAGE mMACHINE kit (Ambion, Austin, TX).
  • Transfection was conducted by using DMRIE-C reagent (Invitrogen, Carlsbad, CA) at the second day. Briefly, OPTI-MEM (1 ml) serum-free medium was mixed with 3 ⁇ l of DMRIE-C reagent by shortly vortexing. The RNAs (5 ⁇ l) from in vitro transcription were added into it and incubated at room temperature for a short time. The transfection mixture was transferred onto the cell monolayer pre-washed by 1 x PBS. After incubation for 3 h at 37 0 C, 5% CO 2 , the transfection mixture was aspirated off and the cells were replenished with EMEM medium (Invitrogen) containing 2% FBS.
  • EMEM medium Invitrogen
  • Example 6 Genetic marker stability in chimeric PRRSV.
  • Viral RNA was extracted from cell culture supernatants with Qiagen Viral RNA Isolation Kit (QIAgen, Valencia, CA). The first-stranded cDNA was synthesized using the Superscript II Reverse Transcription Kit, with the anchor primer Sp2R. PCR amplification of target genomic region was conducted by the use of Pfu Turbo Hotstart DNA polymerase (Stratagene, La Jolla, CA). Specifically, synthesized forward primer SpeF and anchor primer Sp2R were used for amplification of the structural protein-coding region covering ORF3 through 7. After chimeric virus was passed ten times in Marc 145 cells, cell supernatants were collected for isolating viral RNA genome.
  • Specific primer pairs (PSAF, SEQ ID NO: 15 (CCTTAATTAATTTAA ATGGCGCGCC), and SR12709, SEQ ID NO: 16 (CCCCGTCATGCGCAGGTT GTGTAG) were used to perform PCR.
  • the PCR product was about 550 bp on an agarose gel.
  • a field isolate of PRRSV was used as a negative control without PCR amplification.
  • RT-PCR products of cell supernatants were sequenced for confirmation of chimeric virus.
  • Chimeric PRRSV passed in pigs can be isolated from serum collected at day 10 to 14 post inoculation. The stability of genetic marker PSA in PRRSV genome was confirmed after passing in the host animals.
  • Chimeric PRRSV is the similar to the parental PRRSV in viral viability and specificities.
  • the viral titer can reach to 5.686 (1OgTCID 50 /ml) for PRRSPTK-3 and 5.435 (logTCID 50 /ml) for PRRSPTK-6.
  • Example 7 Virulence of chimeric PRRSV in host animals.
  • the virulence of chimeric PRRSV was tested in the host animals.
  • 5 pigs were vaccinated intramuscularly with a combination of PRRSPTK-3 and ptkPRRS (dose is 5x 10 4 for each) and 5 pigs used as control.
  • 5 pigs were vaccinated intramuscularly with a combination of PRRSPTK-3 and PRRSPTK-6 of PRRSV (dose is 5 x 10 5 for each) and 5 pigs used as a control.
  • All pigs were autopsied and the lung lesion scores were determined according to the established standard by clinical pathologist.
  • Example 8 Immunogenecity of chimeric PRRSV in host animals.
  • a combination of PRRSPTK-3 and ptkPRRS was used to vaccinate pigs to test the immunogenicity of chimeric PRRSV.
  • Twenty pigs were divided into 4 groups, 5 pigs per group.
  • Pigs in group 1 and 2 were vaccinated with PRRSptk-3 and ptkPRRS (dosage is 5 x 10 4 for each) and group 3 and group 4 were non-vaccinated controls.
  • pigs in group 1 and group 3 were challenged with virulent heterologous PRRSV NADC-20 and pigs in group 2 and group 3 with PRRSV MN- 184, respectively. After 14 days post challenge, the response to the virulent virus challenge were characterized for all pigs.
  • E. Isolation of Chimeric PRRS Viruses Viremia was evaluated from serum samples by a quantitative real-time PCR amplification. Two combinations of chimeric PRRS virues, PRRSPTK-3/ptkPRRS and PRRSPTK-3/PRRSPTK-6, were used to inoculate 8 pigs, respectively. As shown in Table 2, all pigs were sero-negative at day 0 and all sero-positive at day 14 post- vaccination, indicating that chimeric PRRSV strains remain the replicative feature of modified-live attenuated PRRSV. At day 42 post- vaccination, all pig became seronegative. These results showed that the tested chimeric PRRS viruses were able to remain the replication ability and a limited viremic duration. TABLE 2: Virimia in host animals by chimeric strains.
  • compositions and methods of this invention have been described in terms of exemplary embodiments, it will be apparent to those skilled in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. AU such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention. In addition, all patents and publications listed or described herein are incorporated in their entirety by reference.
  • the invention provides, among other things, an avirulent chimera of PRRSV and a method of its production.
  • avirulent chimera of PRRSV and a method of its production.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des réplicons chimériques du virus respiratoire et reproducteur porcin (PRRSV) d'Amérique du Nord contenant la séquence 5' d'une souche avirulente de PRRSV et une séquence 3' d'une souche virulente de PRRSV. Elle concerne également un procédé de production d'un PRRSV atténué à partir du réplicon chimérique. Elle concerne aussi des compositions contenant le réplicon ou le virus atténué. Elle concerne de plus des vaccins et un procédé de vaccination de porcs contre le PRRSV.
PCT/US2007/071341 2007-06-15 2007-06-15 Construction de prrsv chimères, compositions et préparations vaccinales WO2008153572A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2007/071341 WO2008153572A1 (fr) 2007-06-15 2007-06-15 Construction de prrsv chimères, compositions et préparations vaccinales
CNA2007800005728A CN101454442A (zh) 2007-06-15 2007-06-15 嵌合体prrsv的构建，组合物及疫苗的制备

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/071341 WO2008153572A1 (fr) 2007-06-15 2007-06-15 Construction de prrsv chimères, compositions et préparations vaccinales

Publications (1)

Publication Number Publication Date
WO2008153572A1 true WO2008153572A1 (fr) 2008-12-18

Family

ID=39000553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/071341 WO2008153572A1 (fr) 2007-06-15 2007-06-15 Construction de prrsv chimères, compositions et préparations vaccinales

Country Status (2)

Country Link
CN (1) CN101454442A (fr)
WO (1) WO2008153572A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102107004A (zh) * 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒样颗粒疫苗及其制备方法
CN104694561A (zh) * 2015-02-10 2015-06-10 中国农业科学院上海兽医研究所 表达海肾或萤火虫荧光素酶基因的prrsv重组质粒的构建方法以及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104593336B (zh) * 2014-12-25 2019-05-17 中国农业大学 猪繁殖与呼吸综合征嵌合病毒RvHBJX及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839912A1 (fr) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Clones infectieux de virus à ARN, vaccins et essais diagnostiques
DE10003372A1 (de) * 2000-01-26 2001-08-02 Boehringer Ingelheim Vetmed Rekombinante Attenuation von PRRSV
US20020012670A1 (en) * 2000-01-26 2002-01-31 Knut Elbers Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
WO2002072802A2 (fr) * 2001-03-09 2002-09-19 Boehringer Ingelheim Vetmedica Gmbh Souches vivantes attenuees de virus sdrp
US20030138916A1 (en) * 2002-01-22 2003-07-24 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
US20030186225A1 (en) * 1992-10-30 2003-10-02 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186225A1 (en) * 1992-10-30 2003-10-02 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
EP0839912A1 (fr) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Clones infectieux de virus à ARN, vaccins et essais diagnostiques
DE10003372A1 (de) * 2000-01-26 2001-08-02 Boehringer Ingelheim Vetmed Rekombinante Attenuation von PRRSV
US20020012670A1 (en) * 2000-01-26 2002-01-31 Knut Elbers Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
WO2002072802A2 (fr) * 2001-03-09 2002-09-19 Boehringer Ingelheim Vetmedica Gmbh Souches vivantes attenuees de virus sdrp
US20030138916A1 (en) * 2002-01-22 2003-07-24 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BARFOED A M ET AL: "DNA vaccination of pigs with open reading frame 1-7 of PRRS virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 27-28, 9 September 2004 (2004-09-09), pages 3628 - 3641, XP004526943, ISSN: 0264-410X *
DE LIMA ET AL: "Serologic marker candidates identified among B-cell linear epitopes of Nsp2 and structural proteins of a North American strain of porcine reproductive and respiratory syndrome virus", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 353, no. 2, 30 September 2006 (2006-09-30), pages 410 - 421, XP005654116, ISSN: 0042-6822 *
GREBENNIKOVA T V ET AL: "Genomic characterization of virulent, attenuated, and revertant passages of a North American porcine reproductive and respiratory syndrome virus strain", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 321, no. 2, 10 April 2004 (2004-04-10), pages 383 - 390, XP004499218, ISSN: 0042-6822 *
JIANG ET AL: "Immunogenicity and protective efficacy of recombinant pseudorabies virus expressing the two major membrane-associated proteins of porcine reproductive and respiratory syndrome virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 3, 8 December 2006 (2006-12-08), pages 547 - 560, XP005798908, ISSN: 0264-410X *
MENG X-J ET AL: "SEQUENCE COMPARISON OF OPEN READING FRAMES 2 TO 5 OF LOW AND HIGH VIRULENCE UNITED STATES ISOLATES OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 76, no. PART 12, 1 December 1995 (1995-12-01), pages 3181 - 3188, XP000654509, ISSN: 0022-1317 *
OLEKSIEWICZ M B ET AL: "Epitope mapping porcine reproductive and respiratory syndrome virus by phage display: The nsp2 fragment of the replicase polyprotein contains a cluster of B-cell epitopes", JOURNAL OF VIROLOGY, vol. 75, no. 7, April 2001 (2001-04-01), pages 3277 - 3290, XP002468630, ISSN: 0022-538X *
OLEKSIEWICZ M B ET AL: "Porcine B-cells recognize epitopes that are conserved between the structural proteins of American- and European-type porcine reproductive and respiratory syndrome virus", JOURNAL OF GENERAL VIROLOGY, vol. 83, no. 6, June 2002 (2002-06-01), pages 1407 - 1418, XP002468628, ISSN: 0022-1317 *
OSTROWSKI M ET AL: "Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 76, no. 9, May 2002 (2002-05-01), pages 4241 - 4250, XP002412599, ISSN: 0022-538X *
RODRIGUEZ MARIA JOSE ET AL: "Epitope mapping of the nucleocapsid protein of European and North American isolates of porcine reproductive and respiratory syndrome virus", JOURNAL OF GENERAL VIROLOGY, vol. 78, no. 9, 1997, pages 2269 - 2278, XP002468629, ISSN: 0022-1317 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102107004A (zh) * 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒样颗粒疫苗及其制备方法
CN104694561A (zh) * 2015-02-10 2015-06-10 中国农业科学院上海兽医研究所 表达海肾或萤火虫荧光素酶基因的prrsv重组质粒的构建方法以及应用

Also Published As

Publication number Publication date
CN101454442A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
US20220296699A1 (en) Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
KR100916883B1 (ko) 키메라 아르테리바이러스-유사 입자
JP5793197B2 (ja) 北米型ブタ繁殖・呼吸障害症候群（ｐｒｒｓ）ウイルス及びその使用
KR100996105B1 (ko) 돼지 생식기 호흡기 증후군 바이러스의 ｎ 단백질돌연변이체
KR20110068980A (ko) 고병원성 돼지 생식기 및 호흡기 증후군(ｈｐ ｐｒｒｓ)에 대한 백신
AU2017378336B2 (en) Effective vaccination against European strains of porcine reproductive and respiratory syndrome (PRRS) virus prior to weaning
US9315781B2 (en) Infectious CDNA clone of european PRRS virus and uses thereof
Yuan et al. Construction of infectious cDNA clones of PRRSV: separation of coding regions for nonstructural and structural proteins
US7666585B2 (en) Construction of chimera PRRSV, compositions and vaccine preparations
WO2008153572A1 (fr) Construction de prrsv chimères, compositions et préparations vaccinales
CA2586153C (fr) Virus mutant du syndrome dysgenesique et respiratoire du porc (pprsv)
KR20240019015A (ko) 북미형 및 유럽형 돼지생식기호흡기증후군 바이러스의 키메라 제조방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780000572.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784450

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07784450

Country of ref document: EP

Kind code of ref document: A1